AVIDITY

Serial Number 88808594
Registration 7176498
700

Registration Progress

Application Filed
Feb 24, 2020
Under Examination
Aug 18, 2020
Approved for Publication
Jun 23, 2020
Published for Opposition
Jun 23, 2020
Registered
Sep 26, 2023

Trademark Image

AVIDITY

Basic Information

Serial Number
88808594
Registration Number
7176498
Filing Date
February 24, 2020
Registration Date
September 26, 2023
Published for Opposition
June 23, 2020
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Sep 26, 2023
Registration
Registered
Classes
005 042

Rights Holder

Avidity Biosciences, Inc.

03
Address
10578 Science Drive, Suite 125
San Diego, CA 92121

Ownership History

Avidity Biosciences, Inc.

Original Applicant
03
La Jolla, CA

Avidity Biosciences, Inc.

Owner at Publication
03
San Diego, CA

Avidity Biosciences, Inc.

Original Registrant
03
San Diego, CA

Legal Representation

Attorney
Aaron D. Hendelman

USPTO Deadlines

Next Deadline
1515 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-09-26)
Due Date
September 26, 2029
Grace Period Ends
March 26, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

41 events
Date Code Type Description Documents
Sep 26, 2023 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Sep 26, 2023 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Aug 24, 2023 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Aug 23, 2023 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Jul 28, 2023 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Jul 25, 2023 IUAF S USE AMENDMENT FILED Loading...
Jul 25, 2023 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Mar 2, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 1, 2023 EX5G S SOU EXTENSION 5 GRANTED Loading...
Mar 1, 2023 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Feb 13, 2023 EXT5 S SOU EXTENSION 5 FILED Loading...
Feb 13, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 17, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 15, 2022 EXT4 S SOU EXTENSION 4 FILED Loading...
Aug 15, 2022 EX4G S SOU EXTENSION 4 GRANTED Loading...
Aug 15, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 18, 2022 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Feb 18, 2022 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Feb 18, 2022 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Feb 18, 2022 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Feb 18, 2022 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Feb 16, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 14, 2022 EX3G S SOU EXTENSION 3 GRANTED Loading...
Feb 14, 2022 EXT3 S SOU EXTENSION 3 FILED Loading...
Feb 14, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jul 28, 2021 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 26, 2021 EX2G S SOU EXTENSION 2 GRANTED Loading...
Jul 26, 2021 EXT2 S SOU EXTENSION 2 FILED Loading...
Jul 26, 2021 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Nov 27, 2020 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Nov 25, 2020 EX1G S SOU EXTENSION 1 GRANTED Loading...
Nov 25, 2020 EXT1 S SOU EXTENSION 1 FILED Loading...
Nov 25, 2020 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 18, 2020 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jun 23, 2020 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jun 23, 2020 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jun 3, 2020 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
May 19, 2020 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
May 12, 2020 DOCK D ASSIGNED TO EXAMINER Loading...
Feb 27, 2020 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Feb 27, 2020 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Biological, medicinal and pharmaceutical preparations, namely, oligonucleotide-based therapeutics for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
First Use Anywhere: Nov 4, 2021
First Use in Commerce: Nov 4, 2021
Class 042
providing medical and scientific research information in the fields of pharmaceuticals and biotechnology
First Use Anywhere: Nov 4, 2021
First Use in Commerce: Nov 4, 2021

Classification

International Classes
005 042